OSBPL7-IN-1 |
| Catalog No.GC63339 |
OSBPL7-IN-1 est un inhibiteur de la protéine de liaison À l'oxystérol comme 7 (OSBPL7) actif par voie orale.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1269826-44-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
OSBPL7-IN-1 is an orally active oxysterol binding protein like 7 (OSBPL7) inhibitor. OSBPL7-IN-1 promotes an increase of ABCA1 at the plasma membrane without affecting mRNA expression[1].
OSBPL7-IN-1 (compound G or Cpd G; 1-10 µM) increase plasma membrane ATP-binding cassette transporter (ABCA1) in cultured human podocytes, and significantly increase ABCA1-dependent cholesterol efflux[1].
OSBPL7-IN-1 (100 mg/kg; oral gavage; daily; for 28 days) treatment normalizes proteinuria and prevents renal function decline in mouse models of proteinuric kidney disease[1].
[1]. Matthew B Wright, et al. Compounds targeting OSBPL7 increase ABCA1-dependent cholesterol efflux preserving kidney function in two models of kidney disease. Nat Commun. 2021 Aug 2;12(1):4662.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *